- Home
- MIST vs BOLD Comparison
MIST vs BOLD Comparison
Compare MIST & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIST
- BOLD
- Stock Information
- Founded
- MIST 2003
- BOLD 2018
- Country
- MIST Canada
- BOLD United States
- Employees
- MIST N/A
- BOLD N/A
- Industry
- MIST Biotechnology: Pharmaceutical Preparations
- BOLD
- Sector
- MIST Health Care
- BOLD
- Exchange
- MIST Nasdaq
- BOLD Nasdaq
- Market Cap
- MIST 81.5M
- BOLD 81.0M
- IPO Year
- MIST N/A
- BOLD 2024
- Fundamental
- Price
- MIST $1.43
- BOLD $2.95
- Analyst Decision
- MIST Strong Buy
- BOLD Strong Buy
- Analyst Count
- MIST 3
- BOLD 3
- Target Price
- MIST $13.00
- BOLD $23.00
- AVG Volume (30 Days)
- MIST 177.8K
- BOLD 57.8K
- Earning Date
- MIST 11-11-2024
- BOLD 11-11-2024
- Dividend Yield
- MIST N/A
- BOLD N/A
- EPS Growth
- MIST N/A
- BOLD N/A
- EPS
- MIST N/A
- BOLD N/A
- Revenue
- MIST N/A
- BOLD N/A
- Revenue This Year
- MIST N/A
- BOLD N/A
- Revenue Next Year
- MIST N/A
- BOLD N/A
- P/E Ratio
- MIST N/A
- BOLD N/A
- Revenue Growth
- MIST N/A
- BOLD N/A
- 52 Week Low
- MIST $1.12
- BOLD $2.82
- 52 Week High
- MIST $3.52
- BOLD $15.24
- Technical
- Relative Strength Index (RSI)
- MIST 42.50
- BOLD N/A
- Support Level
- MIST $1.41
- BOLD N/A
- Resistance Level
- MIST $1.53
- BOLD N/A
- Average True Range (ATR)
- MIST 0.07
- BOLD 0.00
- MACD
- MIST -0.01
- BOLD 0.00
- Stochastic Oscillator
- MIST 26.96
- BOLD 0.00
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.